<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-17T19:20:55Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:11351/13787" metadataPrefix="qdc">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:11351/13787</identifier><datestamp>2025-10-24T08:53:21Z</datestamp><setSpec>com_2072_378070</setSpec><setSpec>com_2072_378040</setSpec><setSpec>com_2072_378071</setSpec><setSpec>col_2072_378092</setSpec><setSpec>col_2072_378097</setSpec></header><metadata><qdc:qualifieddc xmlns:qdc="http://dspace.org/qualifieddc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">
   <dc:title>Re-evaluating albumin use in traumatic brain injury</dc:title>
   <dc:creator>Vincent, Jean-Louis</dc:creator>
   <dc:creator>Wiedermann, Christian Josef</dc:creator>
   <dc:creator>Reinstrup, Peter</dc:creator>
   <dc:creator>Ferrer, Ricard</dc:creator>
   <dc:creator>Taccone, Fabio Silvio</dc:creator>
   <dc:subject>Dany cerebral - Tractament</dc:subject>
   <dc:subject>Cap - Ferides i lesions - Tractament</dc:subject>
   <dc:subject>Albúmina - Ús terapèutic</dc:subject>
   <dc:subject>Fluidoteràpia</dc:subject>
   <dc:subject>DISEASES::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Brain Injuries::Brain Injuries, Traumatic</dc:subject>
   <dc:subject>Other subheadings::Other subheadings::/therapy</dc:subject>
   <dc:subject>ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Drug Therapy::Fluid Therapy</dc:subject>
   <dc:subject>CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Albumins</dc:subject>
   <dc:subject>Other subheadings::Other subheadings::/therapeutic use</dc:subject>
   <dc:subject>ENFERMEDADES::enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::lesiones encefálicas::lesiones encefálicas traumáticas</dc:subject>
   <dc:subject>Otros calificadores::Otros calificadores::/terapia</dc:subject>
   <dc:subject>TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::farmacoterapia::fluidoterapia</dc:subject>
   <dc:subject>COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::albúminas</dc:subject>
   <dc:subject>Otros calificadores::Otros calificadores::/uso terapéutico</dc:subject>
   <dcterms:abstract>Albumin; Intracranial pressure; Outcomes</dcterms:abstract>
   <dcterms:abstract>Albúmina; Presión intracraneal; Resultados</dcterms:abstract>
   <dcterms:abstract>Albúmina; Pressió intracranial; Resultats</dcterms:abstract>
   <dcterms:abstract>Traumatic brain injury (TBI) affects approximately 69 million people annually, with the majority of cases being mild-to-moderate in severity. However, in severe TBI, early management is critical and includes fluid resuscitation to control intracranial pressure (ICP) and optimize cerebral perfusion pressure. The SAFE-TBI study linked hypotonic 4% albumin to higher mortality versus saline (33.2% vs. 20.4%; RR 1.63; P = 0.003), likely due to elevated ICP, prompting guidelines favoring saline. However, these recommendations are based on low-quality evidence and overlook hyperoncotic albumin. Preclinical data confirm that hypotonicity—not albumin—drives ICP elevation. Emerging data suggest that hyperoncotic albumin (20–25%) may reduce ICP and improve outcomes. This letter highlights evidence gaps and advocates re-evaluating albumin use in TBI, especially hyperoncotic formulations.</dcterms:abstract>
   <dcterms:abstract>This publication was supported by Grifols.</dcterms:abstract>
   <dcterms:dateAccepted>2025-10-24T08:53:21Z</dcterms:dateAccepted>
   <dcterms:available>2025-10-24T08:53:21Z</dcterms:available>
   <dcterms:created>2025-10-24T08:53:21Z</dcterms:created>
   <dcterms:issued>2025-10-06T09:50:28Z</dcterms:issued>
   <dcterms:issued>2025-10-06T09:50:28Z</dcterms:issued>
   <dcterms:issued>2025-08-01</dcterms:issued>
   <dc:type>info:eu-repo/semantics/article</dc:type>
   <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
   <dc:identifier>http://hdl.handle.net/11351/13787</dc:identifier>
   <dc:relation>Journal of Intensive Care;13(1)</dc:relation>
   <dc:relation>https://doi.org/10.1186/s40560-025-00813-y</dc:relation>
   <dc:rights>Attribution 4.0 International</dc:rights>
   <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
   <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
   <dc:publisher>BMC</dc:publisher>
   <dc:source>Scientia</dc:source>
</qdc:qualifieddc></metadata></record></GetRecord></OAI-PMH>